Clinical trials: Relapsed
Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Promyelocytic Leukemia (M3)
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of decitabine in treating children with relapsed or…
- Conditions
- Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT00042796
- Testing
- decitabine, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
Phase I was a single arm, open label, dose increasing study to explore the safety, tolerance and Cytodynamic characteristics of the drug, and to preliminarily observe the efficacy of the study drug in relapsed / refractory CD7…
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT04480788
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 9 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
B-cell Non Hodgkin Lymphoma
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL).
- Trial name
- Glo-BNHL (NCT05991388)
- Testing
- Odronextamab, Loncastuximab tesirine, Rituximab
- Where
- 11 sites in Australia, Austria and 5 more
- Volunteers
- 210 people
- Sponsor
- University of Birmingham
Relapsed Solid Tumors, Refractory Solid Tumors
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
This IND-exempt Phase I trial will establish the recommended Phase II (RP2D) dose of eribulin in combination with fixed doses of oral irinotecan in adolescents and young adults with relapsed or refractory solid tumors.
- Trial name
- NCT02596503
- Testing
- Eribulin, Irinotecan, Cefixime
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
LAL
A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL
To evaluate the benefit of a precision medicine based strategy (targeted therapeutic options (TTOs)) for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) (in terms of composite remission).
- Trial name
- ALL-TARGET (NCT07522801)
- Testing
- Venetoclax + Tofacitinib, Venetoclax+ Everoliumus +Enrylaze, Venetoclax + 5 Azacitidine
- Where
- 69 sites in Czechia, France and 4 more
- Volunteers
- 93 people
- Sponsor
- Philippe ROUSSELOT
Depression
Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents
This study will determine the effectiveness of cognitive behavioral therapy in preventing a relapse of depressive symptoms in children.
- Trial name
- NCT00158301
- Testing
- Cognitive behavioral therapy (CBT), Drug therapy
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Texas Southwestern Medical Center
Leukemia
STI571 in Treating Patients With Recurrent Leukemia
RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00004932
- Testing
- imatinib mesylate
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer [NK] cells) and how well they work when given together with cyclophosphamide and…
- Conditions
- Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm
- Trial name
- NCT03420963
- Testing
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant.
- Conditions
- Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm
- Trial name
- NCT03807063
- Testing
- Rivogenlecleucel, Rimiducid
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumors, Primary Brain Tumors
Metformin in Children With Relapsed or Refractory Solid Tumors
The purpose of this study is to evaluate the tolerability and safety of escalating doses of metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with recurrent and refractory solid tumors.
- Trial name
- NCT01528046
- Testing
- Vincristine, Irinotecan, Temozolomide
- Where
- 14 sites in United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neuroblastoma, Ewings Sarcoma
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
This treatment study for relapsed high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (CT) antigen specific dendritic cell (DC) vaccine preceded…
- Conditions
- Neuroblastoma, Ewings Sarcoma, Osteogenic Sarcoma, Rhabdomyosarcoma
- Trial name
- NCT01241162
- Testing
- Autologous dendritic cell vaccine with adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Louisville
Neuroblastoma in Children
Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.
Neuroblastoma is a malignant tumor that develops in infants and kids. Dysregulation of histone acetylation is associated with a series of malignant tumors.
- Trial name
- CSIIT-Q36 (NCT05338541)
- Testing
- Tucidinostat and etoposide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yizhuo Zhang
Multiple Sclerosis, Relapsing Remitting
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is…
- Trial name
- NCT02247310
- Testing
- Interferon beta-1b (Betaferon®, BAY 86-5046), BETACONNECT
- Where
- 11 sites in Austria, Belgium and 9 more
- Volunteers
- 498 people
- Sponsor
- Bayer
Takayasu's Arteritis, Giant Cell Arteritis
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Background: Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse.
- Conditions
- Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis
- Trial name
- NCT02257866
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Engraft Failure, Relapse
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
The investigators will conduct this prospective and randomized clinical trial, to evaluate the hematopoietic reconstitution, GVHD and relapse rate of patients after allo-HSCT with decitabine containing conditional regimen and NAC…
- Conditions
- Engraft Failure, Relapse, GVHD
- Trial name
- NCT04945096
- Testing
- decitabine, Acetylcysteine, Semustine
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and dexrazoxane in treating children and adolescents who have relapsed or refractory solid tumors.
- Trial name
- NCT00039481
- Testing
- oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
RATIONALE: Seneca Valley virus-001 may be able to kill certain kinds of tumor cells without damaging normal cells. Adding low dose cyclophosphamide (in part B of study) may help to kill even more tumor cells.
- Conditions
- Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma
- Trial name
- NCT01048892
- Testing
- Seneca Valley virus-001, cyclophosphamide, laboratory biomarker analysis
- Where
- 18 sites in United States
- Volunteers
- 22 people
- Sponsor
- Children's Oncology Group
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory).
- Conditions
- Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT05071209
- Testing
- Elimusertib
- Where
- 29 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Tumor, Pediatric, Leukemia
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00357500
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Orthodontic Relapse
Efficacy and Cost-effectiveness of Orthodontic Retention Protocols
Objective is to assess changes of dentition and periodontium, and hygiene in retention after the end of the active phase of orthodontic treatment, and relationship with gender, type of retention appliance, pre-therapeutic…
- Trial name
- orthoretenti (NCT05121220)
- Testing
- fixed retainer, removable retainer
- Where
- Croatia
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Poliklinika Orthonova